Correction to: Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway (Hepatology, (2013), 57, 3, (1088-1097), 10.1002/hep.26188);Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/E2F transcription factor 1-dependent apoptotic pathway

Hepatology

Volumn 57, Issue 3, 2013, Pages 1088-1097

  Sun, Hai Xiang ^a,b   Xu, Yang ^a,b   Yang, Xin Rong ^a   Wang, Wei Min ^a   Bai, Haibo ^b   Shi, Ruo Yu ^a   Nayar, Suresh K ^b   Devbhandari, Ranjan P ^a   He, Yi Zhou ^a   Zhu, Qin Feng ^a,b   Sun, Yun Fan ^a   Hu, Bo ^a   Khan, Mehtab ^b   Anders, Robert A ^b   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 2ALPHA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DIMERIZATION PARTNER 3; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENICITY; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT PLASMID; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

EID: 84874484590     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29735     Document Type: Erratum

References (41)

1. Menrad H, Werno C, Schmid T, Copanaki E, Deller T, Dehne N, Brune B. Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids. HEPATOLOGY 2010; 51: 2183-2192.
2. Dai CX, Gao Q, Qiu SJ, Ju MJ, Cai MY, Xu YF, et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 2009; 9: 418.
3. Xie H, Song J, Liu K, Ji H, Shen H, Hu S, et al. The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients' prognosis and hepatitis B virus X protein. Dig Dis Sci 2008; 53: 3225-3233.
4. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12: 9-22.
5. Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, et al. HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A 2010; 107: 14182-14187.
6. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13: 167-171.
7. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-685.
8. Skuli N, Simon MC. HIF-1alpha versus HIF-2alpha in endothelial cells and vascular functions: is there a master in angiogenesis regulation? Cell Cycle 2009; 8: 3252-3253.
9. Skuli N, Liu L, Runge A, Wang T, Yuan L, Patel S, et al. Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood 2009; 114: 469-477.
10. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A 1997; 94: 4273-4278.
11. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007; 11: 335-347.
12. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003; 13: 493-501.
13. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001; 85: 881-890.
14. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003; 4: 133-146.
15. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005; 8: 131-141.
16. Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF, Jing S. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol 2007; 13: 3176-3182.
17. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-2593.
18. Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010; 70: 8045-8054.
19. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB, et al. CD151 amplifies signaling by integrin alpha6beta1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology 2011; 140: 1629-1641 e1615.
20. Mignotte B, Vayssiere JL. Mitochondria and apoptosis. Eur J Biochem 1998; 252: 1-15.
21. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 1998; 95: 4997-5002.
22. Qiao H, Di Stefano L, Tian C, Li YY, Yin YH, Qian XP, et al. Human TFDP3, a novel DP protein, inhibits DNA binding and transactivation by E2F. J Biol Chem 2007; 282: 454-466.
23. Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W, Dong XY, et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 2002; 169: 1102-1109.
24. Milton A, Luoto K, Ingram L, Munro S, Thangue NB. A functionally distinct member of the DP family of E2F subunits. Oncogene 2006; 25: 3212-3218.
25. Hitchens MR, Robbins PD. The role of the transcription factor DP in apoptosis. Apoptosis 2003; 8: 461-468.
26. Putzer BM. E2F1 death pathways as targets for cancer therapy. J Cell Mol Med 2007; 11: 239-251.
27. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH. p14ARF links the tumour suppressors RB and p53. Nature 1998; 395: 124-125.
28. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2004; 2: 203-214.
29. Fogal V, Kartasheva NN, Trigiante G, Llanos S, Yap D, Vousden KH, Lu X. ASPP1 and ASPP2 are new transcriptional targets of E2F. Cell Death Differ 2005; 12: 369-376.
30. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000; 407: 645-648.
31. He C, Sun XP, Qiao H, Jiang X, Wang D, Jin X, et al. Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma. Cancer Sci, 2012; 103: 528-534.
32. Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002; 4: 859-864.
33. Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001; 3: 552-558.
34. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
35. Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ 2008; 15: 628-634.
36. Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, et al. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 2008; 99: 2055-2061.
37. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 2012; 40: 1733-1747.
38. Kim KR, Moon HE, Kim KW. Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl) 2002; 80: 703-714.
39. Tian C, Lv D, Qiao H, Zhang J, Yin YH, Qian XP, et al. TFDP3 inhibits E2F1-induced, p53-mediated apoptosis. Biochem Biophys Res Commun 2007; 361: 20-25.
40. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, et al. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 2009; 119: 2160-2170.
41. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-21.